A study of two forms of letrozole combined with ribociclib for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new version of the hormone therapy drug letrozole (called Letrozole SIE) against the standard version (Femara). Both are combined with ribociclib, a drug that helps stop cancer cells from growing. The goal is to see if the new version works just as well and is safe for postmenopausal women with advanced breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who has gone through menopause.
- Your breast cancer is hormone-receptor-positive (HR+) and HER2-negative.
- Your cancer is locally advanced or has spread to other parts of the body and cannot be removed with surgery.
- You have not received any systemic treatment (like chemotherapy or hormone therapy) for advanced breast cancer.
- You are generally able to take care of yourself (ECOG performance status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
This study compares a new injectable form of the drug letrozole with the standard oral pill. It aims to find out if the injection works as well as the pill for women who have already taken letrozole for their early breast cancer and have finished their initial treatment.
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
Hear when a new Advanced/Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.